TransMedics Group, Inc. — Q1 2024 Form 10-Q
Business and period: Unaudited results for the three months ended March 31, 2024, compared with the same 2023 period. TransMedics sells its Organ Care System (OCS) products and provides organ retrieval, management and logistics through its National OCS Program (NOP). The company reports as one operating segment.
Financial highlights
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Total revenue | $96.9 million | $41.6 million; up 133% |
| Net product revenue | $61.3 million | $34.0 million; up 80% |
| Service revenue | $35.5 million | $7.6 million; up 370% |
| Gross profit and margin | $60.0 million; 62% | $28.8 million; 69% |
| Operating income (loss) | $12.4 million | $(2.1) million |
| Net income (loss) | $12.2 million; $0.37 basic and $0.35 diluted per share | $(2.6) million; $(0.08) per share |
| Operating cash flow | $(3.4) million | $(8.7) million |
| Capital expenditures | $44.2 million | $0.9 million |
Cash and cash equivalents were $350.2 million at March 31, 2024, down from $394.8 million at December 31, 2023. Cash, cash equivalents and restricted cash declined $44.6 million during the quarter. The company attributed most investing cash use to property and equipment purchases, including $39.4 million of increased transplant-related aircraft. Accounts receivable rose to $81.9 million from $63.6 million at year-end, and inventory rose to $48.5 million from $44.2 million.
At March 31, total liabilities were $564.4 million and stockholders’ equity was $159.5 million. Debt comprised $460 million principal of 1.50% convertible notes due 2028 (carrying value $447.8 million) and $60 million principal of CIBC debt (carrying value $59.1 million). The notes’ estimated fair value was $506.4 million. CIBC debt carried a stated rate of 7.3%; the company reported compliance with its covenants. Current assets were $488.3 million versus current liabilities of $50.2 million.
Changes and management commentary
- U.S. OCS transplant revenue increased to $91.9 million from $37.5 million, mainly on higher disposable-set volumes across liver, heart and lung. Revenue outside the U.S. was approximately $4.1 million in both periods. No customer represented more than 10% of revenue or accounts receivable.
- Service growth reflected greater NOP utilization and the logistics offering, as well as $0.9 million of Summit legacy flight-school revenue. Summit was acquired in August 2023; its legacy charter and aircraft-management customers were transitioned to third parties.
- Gross margin fell to 62% from 69%, principally because services, which have lower margins than products, became a larger share of revenue. Product gross margin was 77% versus 79%; service gross margin improved to 36% from 27%, which management attributed primarily to NOP efficiency and scale.
- Research, development and clinical-trial expense increased to $11.4 million from $5.9 million, reflecting next-generation OCS and other development work. SG&A rose to $36.2 million from $25.0 million, primarily due to personnel and facility costs. Stock-based compensation was $6.9 million, up from $3.9 million.
Outlook, risks and contingencies
No specific quarterly or full-year revenue or earnings guidance is provided in the filing. Management expects long-term revenue growth from expanded NOP use and non-U.S. adoption, while anticipating increased spending on commercial expansion, logistics and aircraft, manufacturing and sterilization capacity, and product development. Management believes existing cash will cover operations, capital expenditures and debt service for at least 12 months after filing, but says additional funding may be needed in the future. It also expects overall gross margin to fluctuate and notes that a higher service-revenue mix may reduce it.
Key risks include market adoption and reimbursement, regulatory approvals, competition, scaling manufacturing and sterilization, reliance on limited-source suppliers, and operating and transportation costs. The company also cites uncertainty around HRSA initiatives and changes to operation of the U.S. Organ Procurement and Transplantation Network. It had no material legal proceedings and no accrued indemnification liabilities. A non-cancellable purchase commitment had $6.0 million remaining as of March 31, 2024, with purchases extending through 2029. The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether revenue growth—especially U.S. liver and NOP-related growth—continues, and how much is attributable to product volumes versus services.
- Whether NOP service-margin improvement can continue while the service mix pressures overall gross margin.
- Whether aircraft investment and other capital spending translate into sustainable cash generation; Q1 operating cash flow remained negative despite net income.
- Debt terms, conversion and potential dilution from the $460 million notes, and ongoing compliance with CIBC covenants.
- Management’s 12-month liquidity assessment and the potential need for additional financing as expansion and development spending increase.